Analytical Data
-
Gene name
PCI
- Application
-
Alternative Names
SERPINA5; PAI3; PLANH3; PROCI; Serpin Peptidase Inhibitor Clade A 5; Plasma Serine Protease Inhibitor; Plasminogen Activator Inhibitor 3; Acrosomal serine protease inhibitor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05154
-
Expression Region
Ser43~Pro406
-
Molecular Weight
45kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PCI (protein-conjugated immunotherapy) recombinant proteins have emerged as a pivotal focus in the field of immunotherapy, particularly in the context of cancer treatment. The human immune system is capable of targeting and eliminating cancer cells; however, tumors have developed various mechanisms to evade immune detection. Recombinant proteins, particularly those that are conjugated with tumor-associated antigens, can effectively enhance the immune response by presenting specific epitopes that stimulate T-cell activation and proliferation. This approach not only aids in educating the immune system to recognize and attack cancerous cells but also provides a targeted strategy to minimize damage to healthy tissues. Recent advances in genetic engineering and protein synthesis techniques have facilitated the design and production of these recombinant proteins, allowing for improved efficacy and safety profiles. Ongoing research explores various formulations, combination therapies, and delivery methods to optimize the immune response further. Moreover, the utilization of adjuvants in conjunction with PCI recombinant proteins aims to bolster immune activation and prolong the therapeutic effects. The burgeoning field of PCI recombinant proteins holds promise in establishing more effective cancer treatment modalities, paving the way for personalized medicine and improving clinical outcomes for patients suffering from malignancies. As this area of research evolves, it may offer significant insights into overcoming the limitations of traditional cancer therapies and contribute to the broader understanding of immune regulation in oncological contexts.
